Harpoon Therapeutics Inc (HARP) Stock
HARP is no longer traded. Harpoon Therapeutics was delisted from the Nasdaq in March 2024.
Prices on this page are historical; the last trade was March 8, 2024 at $23.01.
Harpoon Therapeutics stock price history
HARP final trading statistics
- Final close
- $23.01
- Final trading day
- Mar 8, 2024
- Market cap at delisting
- $492.35M
- Shares outstanding
- 21.40M
- Final 52-week range
- $0.54 – $23.21
- Avg. volume (final 3 mo.)
- 1,219,604
- All-time high (split-adj.)
- $247.20 · May 2020
- All-time low (split-adj.)
- $3.29 · Oct 2023
- Return since IPO
- -83.0%
- Beta
- 2.10
- Book value / share
- $1.10
- Price / book
- 20.82
Harpoon Therapeutics annual financials
| Fiscal year | Revenue | Net income | EPS |
|---|---|---|---|
| FY2023 | $37.34M | -$30.5M | — |
| FY2022 | $31.91M | -$67.1M | -$2.05 |
| FY2021 | $23.65M | -$166.4M | -$2.06 |
| FY2020 | $17.44M | -$46.4M | -$2.00 |
| FY2019 | $5.78M | -$52.0M | -$2.64 |
Last five fiscal years reported before the delisting; fiscal year ending December. EPS is adjusted (non-GAAP) EPS as reported. Source: company filings via EODHD.
About Harpoon Therapeutics Inc
Harpoon Therapeutics, Inc., a clinical-stage immunotherapy company, engages in the development of a novel class of T cell engagers that harness the power of the body's immune system to treat patients suffering from cancer and other diseases in the United States. The company develops tri-specific T cell activating construct (TriTAC) product candidate, including HPN328, which is in Phase I/II clinical trials for the treatment of small cell lung cancer and other Delta-like canonical Notch ligand 3-expressing tumors; and HPN217 that is in Phase I clinical trials for the treatment of multiple myeloma. Its preclinical stage product is HPN601 for the treatment of multiple solid tumor indications. It has a discovery collaboration and license agreement with AbbVie Biotechnology Ltd. to develop and commercialize products that incorporate its proprietary TriTAC platform technology together with soluble T cell receptors. The company was incorporated in 2015 and is headquartered in South San Francisco, California. As of March 11, 2024, Harpoon Therapeutics, Inc. operates as a subsidiary of Merck Sharp & Dohme LLC.
Harpoon Therapeutics stock FAQ
What happened to Harpoon Therapeutics stock?
Harpoon Therapeutics stock was delisted from the Nasdaq. Its final close was $23.01 on March 8, 2024.
Is HARP stock still trading?
No. HARP was delisted from the Nasdaq in March 2024 and no longer trades on a U.S. exchange.
What was the last price of HARP stock?
HARP closed at $23.01 on its final trading day, March 8, 2024, for a market value of about $492.35M.
What were Harpoon Therapeutics's revenue and earnings in its last full fiscal year?
Harpoon Therapeutics reported revenue of $37.34M and net income of -$30.5M in fiscal 2023, its last full year as a public company.
When did Harpoon Therapeutics go public?
Harpoon Therapeutics Inc stock began trading on February 8, 2019.